Creso Pharma Ltd plunges on ASX

Launch of Innovative Infused Terpene Blended Craft Beers and Adult Drinks: Creso Pharma Ltd.’s (ASX: CPH) stock fell 3% on June 29, 2018 despite the fact that the group lately revealed that its CLV Frontier Brands Pty Ltd (CLV) JV with LGC Capital and the Baltic Beer Company launched its beverage business unit. They are coming up with a number of products ready for commercial launch. The R&D brewery facility in Tallinn, Estonia is now complete and is being fully used for research and development of a range of CLV beers and adult soft drinks. Once they are market-ready, CLV has agreements in place with brewing and bottling partners to produce the products/beverages. Further, the first two beers that will be released soon under the new CLV umbrella beer brand OLD BOY MARY JANE (OBMJ) are fermenting at the facilities of CLV’s brewing partner. These 2 new beers OBMJ Ghost Bog Hazy IPA and OBMJ Improper Kölsch will be packed and ready for shipments during July 2018. Additionally, the initial focus for these bottled beers is the UK market, after that it will be other European and global markets. The company has started discussions and has advanced in Canada regarding licensed production in cans. The discussions are also in progress with distributors in Australia, Israel and a number of other key markets. Furthermore, currently adult soft drinks are in the final stage of development. The company’s brand websites are planned to go live with social media campaigns ready for launch in the coming weeks. In addition, UK portfolio is set for launch in September 2018 at the Boutique Bar Show in London with a wider European launch planned for October 2018 at the Anuga Exhibition in Cologne Germany. Meanwhile, CPH stock has fallen 14.47% in three months as on June 28, 2018.


Disclaimer

The advice given by Kalkine Pty Ltd and provided on this website is general information only and it does not take into account your investment objectives, financial situation or needs. You should therefore consider whether the advice is appropriate to your investment objectives, financial situation and needs before acting upon it. You should seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice. Not all investments are appropriate for all people. Kalkine.com.au and associated websites are published by Kalkine Pty Ltd ABN 34 154 808 312 (Australian Financial Services License Number 425376). The information on this website has been prepared from a wide variety of sources, which Kalkine Pty Ltd, to the best of its knowledge and belief, considers accurate. You should make your own enquiries about any investments and we strongly suggest you seek advice before acting upon any recommendation. Kalkine Pty Ltd has made every effort to ensure the reliability of information contained in its newsletters and websites. All information represents our views at the date of publication and may change without notice. To the extent permitted by law, Kalkine Pty Ltd excludes all liability for any loss or damage arising from the use of this website and any information published (including any indirect or consequential loss, any data loss or data corruption). If the law prohibits this exclusion, Kalkine Pty Ltd hereby limits its liability, to the extent permitted by law to the resupply of services. There may be a product disclosure statement or other offer document for the securities and financial products we write about in Kalkine Reports. You should obtain a copy of the product disclosure statement or offer document before making any decision about whether to acquire the security or product. The link to our Terms & Conditions has been provided please go through them and also have a read of the Financial Services Guide. On the date of publishing this report (mentioned on the website), employees and/or associates of Kalkine Pty Ltd do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s